New tests previously performed using alternative methods (e.g. Atomic Absorption, Nephelometry, Potentiometry) on different instruments, the necessity for clinical laboratories to overhaul and improve their services in terms of turnaround time, breadth and depth of test menu, quality of results, and in general new value added, together with dwindling economic resources and the availability of high-throughput random-access analysers integrating in-line immunochemistry testing modules have significantly changed the nature of laboratory work. Work is no longer strictly partitioned between diagnostic areas and an increasing number of lab activities are being merged. To address this challenge Sentinel and Abbott’s scientific and technical work teams have joined forces. We here report on the outcome of this collaboration for the optimisation of 17 in-vitro diagnostic products (Sentinel) and their validation for routine use of the Abbott AEROSET® and ARCHITECT® c8000 analysers according to the requirements of the European Directive 98/79/CE.